Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Saturated fat and cardiovascular disease wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Cardiovascular disease wikipedia , lookup
Quantium Medical Cardiac Output wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Jatene procedure wikipedia , lookup
Drug-eluting stent wikipedia , lookup
History of invasive and interventional cardiology wikipedia , lookup
Myocardial infarction wikipedia , lookup
IDEAL Trial Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial Presented at The American Heart Association Scientific Session 2005 Presented by Dr. Terje Pedersen IDEAL Trial: Background • Several recent studies have evaluated a regimen of high-dose statin compared with a lower-dose, usual care statin regimen in the setting of stable or unstable acute coronary syndromes, including TNT, PROVE-IT TIMI-22 and A to Z. • In the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT TIMI22) study of patients recently hospitalized with acute coronary syndromes, aggressive lipid lowering with 80 mg per day of atorvastatin provided more protection from death and cardiovascular events than 40 mg per day of pravastatin. • The Treating to New Targets (TNT) study demonstrated that aggressive lipid lowering with 80 mg per day of atorvastatin provided greater protection from major cardiovascular events than low-dose atorvastatin in stable CHD patients. • On the other hand, the Aggrastat to Zocor (A to Z) trial showed that treatment with high-dose simvastatin failed to show a significant reduction in the primary composite endpoint of cardiovascular death, MI readmission for ACS or stroke. www. Clinical trial results.org Presented at AHA 2005 IDEAL Trial: Study Design 8,888 patients ≤80 years with definite history of myocardial infarction and qualified for stain therapy at time of recruitment Pts. on statin therapy at baseline: simvastatin (50%), atorvastatin (11%), pravastatin (10%); baseline LDL 121.5 mg/dL; total cholesterol 196 mg/dL; median time from last MI 21 mos in atorvastatin group, 22 mos in simvastatin group 19% female, mean age 62 yrs, fasting blood samples were obtained at baseline, 12 weeks, 24 weeks, 1 year and each year thereafter, mean follow-up median of 4.8 years Randomized High-dose atorvastatin Standard-dose simvastatin 80 mg/day If LDL was <40 mg/dL at 24 wks dose could be reduced to 40 mg/day 20 mg/day If cholesterol >190 mg/dL at 24 wks dose could be increased to 40 mg/day n=4,439 n=4,449 Primary Endpoint: Composite of major coronary event, defined as coronary death, hospitalization for non-fatal acute MI or resuscitated cardiac arrest. Secondary Endpoint: Major cardiovascular events, anyCHD event, hospitalization with a primary diagnosis of congestive heart failure, peripheral artery disease, any cardiovascular events and all-cause mortality. www. Clinical trial results.org Presented at AHA 2005 IDEAL Trial: Primary Endpoint Primary Composite of major coronary event * (%) p = 0.07 12 10.4 9.3 • The primary composite endpoint of major coronary event occurred in 9.3% of the atorvastatin group and 10.4% of the simvastatin group. % 9 6 3 0 Atorvastatin www. Clinical trial results.org Simvastatin * Major coronary event defined as coronary death, hospitalization for non-fatal acute MI or resuscitated cardiac arrest. Presented at AHA 2005 IDEAL Trial: Primary Endpoint cont. • Among the components of the primary endpoint, there was no difference in CHD death or cardiac arrest with resuscitation, but nonfatal MI occurred less frequently in the atorvastatin group. p=0.02 8 7.2 6.0 % 6 4 p=0.90 3.9 4.0 p=NS 2 0.2 0.2 0 CHD death Cardiac arrest with resuscitation Atorvastatin www. Clinical trial results.org Nonfatal MI Simvastatin Presented at AHA 2005 IDEAL Trial: Secondary Endpoints Major cardiovascular events and any cardiovascular event (%) p<0.001 32 30.8 26.5 24 • Major cardiovascular events, defined as any primary event plus stroke, occurred less often in the atorvastatin group. % p=0.02 16 12.0 13.7 8 0 Major CV events Atorvastatin www. Clinical trial results.org Any CV event •Any cardiovascular event, defined as major CV event plus hospitalization for CHF and peripheral artery disease, also occurred less often in the atorvastatin group. Simvastatin Presented at AHA 2005 IDEAL Trial: Serious Adverse Events Serious adverse events and adverse event resulting in permanent study drug discontinuation (%) p=0.42 48% 47.4 46.5 40% % 32% 24% p<0.001 16% 9.6 8% 4.2 • There was no difference in the frequency of serious adverse events, but adverse event resulting in permanent drug discontinuation was more frequent in the atorvastatin group. • Liver enzyme elevation occurred more frequently in the atorvastatin group as did myalgia. 0% SAE Atorvastatin www. Clinical trial results.org SAE drug discontinuation Simvastatin Presented at AHA 2005 IDEAL Trial: Serious Adverse Events cont. Liver enzyme elevation and myalgia (%) 2.2% p<0.001 2% p<0.001 % ALT >3x upper limit of normal 1% 1.1% 0.97% •Liver enzyme elevation occurred more frequently in the atorvastatin group as did myalgia. 0.11% 0% Liver Enzyme Elevation Atorvastatin www. Clinical trial results.org Myalgia Simvastatin Presented at AHA 2005 IDEAL Trial: Summary • Among patients with a previous myocardial infarction, treatment with high-dose atorvastatin was associated with a directional but nonsignificant reduction in the primary composite endpoint of major coronary events compared with standard dose simvastatin at five year follow-up. • The present trial further extends the evaluation of aggressive lipidlowering to the setting of post-myocardial infarction patients. • While there was a reduction in the secondary endpoint of recurrent MI, adverse events and liver enzyme elevations were more frequent in the high-dose atorvastatin group, highlighting the need for careful monitoring of patients on this regimen. www. Clinical trial results.org Presented at AHA 2005